SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race

opakalimazetukalnerPositive

AI Analysis

Summary

SK acquired Biohaven's opakalim for $795 million, a potassium channel opener for focal epilepsy that is expected to compete with Xenon's azetukalner in an upcoming pivotal readout.

Clinical Trial Data

Phase

pivotal

Outcome Details

$795 million deal for opakalim, a potassium channel opener for focal epilepsy

Importance:7/10

Sentiment:

0.60

acquisitionepilepsypotassium channel openerpivotal trialfocal epilepsy

Related Companies

$BHVN

Read the original article

Published by Pharmaceutical Technology on August 27, 2026 1:40 PM

Read Original